arrow
N

Neema Navai

ut md anderson cancer center
H指数:27
被引数:2,836

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PROGNOSTIC OUTCOMES COMPARING UPFRONT RADICAL CYSTECTOMY AND PRIMARY BCG THERAPY IN VERY-HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER: AN UPDATED ANALYSIS IN THE MODERN BCG ERA

比较超高危非肌层浸润性膀胱癌患者的一线根治性膀胱切除术与初始BCG治疗的预后结局:现代BCG时代的更新分析

2026-05-010
PRE
A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer

最佳全身疗法与最佳全身疗法对转移性前列腺癌原发肿瘤进行确定性治疗的2期随机对照试验

2026-03-140
PRE
Metastasis-directed radiotherapy for oligometastatic urothelial carcinoma of the bladder and upper tract

寡转移性膀胱及上尿路尿路上皮癌的转移灶定向放射治疗

2026-01-010
PRE
Dysregulated mitochondrial energy metabolism drives the progression of mucosal field effects to invasive bladder cancer

线粒体能量代谢失调驱动黏膜区域效应向侵袭性膀胱癌的进展

2025-09-250
OAAI
Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group

Gupta, S.; Hensley, P.J.; Li, R.; Choudhury, A.; Daneshmand, S.; Faltas, B.M.; Flaig, T.W.; Grass, G.D.; Grivas, P.; Hansel, D.E. 肌层浸润性膀胱癌的保膀胱策略:国际膀胱癌小组的建议。Eur. Urol. 2025, 已接受待发表。 [Google Scholar] [CrossRef]

2025-04-220
PRE
Loss of LPAR6 and CAB39L dysregulates the basalto-luminal urothelial differentiation program, contributing to bladder carcinogenesis
2024-05-011
OAAI
Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy

用卡介苗或早期根治性膀胱切除术治疗欧洲泌尿外科协会极高危非肌层浸润性膀胱癌患者的肿瘤学结果

2023-12-0111
PRE
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract
2023-12-013
PRE
Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer

序贯膀胱内吉西他滨和多西他赛是卡介苗芽孢杆菌的替代品,用于治疗中危非肌层浸润性膀胱癌

2023-10-0118
PRE
Impact of age >70 years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin

年龄> 70岁对卡介苗治疗非肌层浸润性膀胱癌患者肿瘤学结局的影响

2023-08-028
PRE
Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes

卡介苗无反应的非肌层浸润性膀胱癌患者的保留膀胱治疗: 长期生存结果分析

2023-07-019
OAAI